Bio-Techne TECH
United StatesHealthcare · BiotechnologyUSD
70.50 USD (−2.8%)
10 analysts
Trading 2120.30 €Open account ↗
Lightyear0.90 €Open account ↗
N260.90 €Open account ↗
XTB1.00 €★ featured · affiliateOpen account ↗Trading 2120.30 €Open account ↗Lightyear0.90 €Open account ↗XTB1.00 €★ featured · affiliateOpen account ↗200.00 € order · cheapest cheapest available in your country iCompare all 22 brokers →What does it do?
Bio-Techne is a life sciences company that develops and sells biological research tools, recombinant proteins, and clinical diagnostic products for laboratories and pharmaceutical and biotechnology companies.
Key points
from its scores- ✓Very solid balance sheet8.4
- ✕Demanding valuation2.5
- ✕Weak growth4.6
- ✕Little or no dividend4.6
AI analysis
bottom line, main risk, context and newsThe quality of the business and the balance sheet are good, but the current valuation leaves no margin of safety for such moderate growth.
Bio-Techne shows solid financial health (score 8.36) with minimal debt (ND/EBITDA of 0.07) and an operating margin of 27.87%, but its valuation is very demanding (P/E of 62.53) and its revenue growth is weak (1.30%), which weighs on its attractiveness at these prices.
The main risk is valuation: with a P/E of 62.53 and revenue growth of only 1.30%, any earnings disappointment could trigger a significant correction in the share price.
Context and risks
No recent relevant news and no material exposure to current macro factors (rates, energy, tariffs). The research and diagnostics products business has a healthy balance sheet (Net Debt/EBITDA of 0.07) that insulates it from the rate tightening, and its margin profile does not depend on commodities or shipping routes.
Is Bio-Techne stock cheap or expensive?
at the analysis dateOn P/E and EV / EBITDA, it trades 135% above the Healthcare median on average.
| Multiple | Company | Sector | Difference |
|---|---|---|---|
| P/E | 62.5 | 26.7 | +134% |
| EV / EBITDA | 34.1 | 14.5 | +135% |
| Price / book | 5.4 | 4.1 | +31% |
| Price / sales | 9.4 | 3.4 | +174% |
Sector: median of the 217 Healthcare companies analysed. In bold, the multiples used for the comparison.
Valuation score: 2.5 out of 10 (median for Healthcare: 4.7).
Average analyst target: 70.50 USD, −2.8% versus the price.
A premium can be justified if the company is of higher quality or grows faster than its sector: Quality / Moat 6.8 (sector 5.5), Growth 4.6 (sector 6.6).
Classic formulas with standard assumptions (10.0% growth, 8-9% discount rate). Indicative only: they change a lot with the assumptions and are not a recommendation.
Work out its fair value yourself →How much would you have made investing every month? →
Comparing it with its sector does not say whether it is a good buy: this is not investment advice.
Score by category
0 to 10 · hover overtap each one to see what it measuresKey metrics
at the analysis date · compared with the Healthcare medianValuation
- P/E
- 62.5
- Forward P/E
- 31.4
- EV / EBITDA
- 34.1
- Price / book
- 5.4
- Price / sales
- 9.4
- PEG
- 2.11
- Market cap
- 11.4B USD
- Enterprise value
- 11.4B USD
Profitability
- ROE
- 9.0%
- ROA
- 6.7%
- ROIC (approx.)
- 14.1%
- Gross margin
- 66.2%
- Operating margin
- 27.9%
- Net margin
- 15.0%
- Free cash flow
- 229.7M USD
- FCF yield
- 2.0%
- Cash conversion
- 69%
Solvency
- Total debt
- 289.1M USD
- Net debt
- 23.6M USD
- Cash
- 265.5M USD
- EBITDA
- 334.1M USD
- Net debt / EBITDA
- 0.07
- Debt / equity
- 13.71
- Current ratio
- 4.55
- Quick ratio
- 2.94
Growth
- Revenue growth
- +1.3%
- EPS (TTM)
- 1.16 USD
- EPS (forward)
- 2.31 USD
Dividend
- Dividend yield
- 0.4%
- Payout
- 27.6%
Risk and market
- Beta
- 1.29
- Analyst consensus
- Hold (10)
- Target price
- 70.50 USD
- 52-week range
- 43.20 – 72.69
Recent news
All TECH news →Compare it with its sector
All 217 in Healthcare →Frequently asked questions about Bio-Techne
Is Bio-Techne stock cheap or expensive?
On P/E and EV / EBITDA, it trades 135% above the Healthcare median on average. Valuation score: 2.5 out of 10 (median for Healthcare: 4.7). Average analyst target: 70.50 USD, −2.8% versus the price. This is not investment advice.
What score does Bio-Techne get on MeridIAn Screener?
It scores 5.4 out of 10, rank 1,506 of 2,130 (better than 29% of the companies analysed). Its strongest category is Financial health (8.4) and its weakest, Valuation (2.5). Analysis of 08/10/2026.
What is Bio-Techne's P/E ratio?
Its P/E is 62.5: the share price equals 62.5 times earnings per share over the last 12 months. The Healthcare median is 26.7. Based on the earnings analysts expect, the forward P/E is 31.4.
How much is Bio-Techne worth on the stock market?
Its market capitalisation is 11.4B USD and its enterprise value, debt included, is 11.4B USD.
How much debt does Bio-Techne have?
Its net debt (debt minus cash) is 23.6M USD. That is 0.07 times its EBITDA; the Healthcare median is 1.53.
Does Bio-Techne pay a dividend?
Yes: its dividend yield is 0.44% and it pays out 28% of its earnings.
How has Bio-Techne stock performed over the last year?
It has risen 24.3% over the last year, excluding dividends. Over the last 52 weeks it has traded between 43.20 and 72.69 USD. Past performance does not guarantee future results.
What do analysts think of Bio-Techne?
10 analysts cover it; their average recommendation is “Hold” and their average target is 70.50 USD (−2.8% versus the price). It is an estimate, not market data.